From the Blood Research Institute, Blood Center of Wisconsin, Milwaukee (P.E.R.E., S.A.M., N.D.M., A.E.M.); Department of Biochemistry, University of Wisconsin-Madison (M.P.W.); and Department of Cell Biology, Neurobiology and Anatomy, Medical College of Wisconsin, Milwaukee (A.E.M.).
Arterioscler Thromb Vasc Biol. 2014 Jan;34(1):187-95. doi: 10.1161/ATVBAHA.113.302660. Epub 2013 Nov 14.
Tissue factor pathway inhibitor (TFPI) blocks the initiation of coagulation by inhibiting TF-activated factor VII, activated factor X, and early prothrombinase. Humans produce two 3' splice variants, TFPIα and TFPIβ, which are differentially expressed in endothelial cells and platelets and possess distinct structural features affecting their inhibitory function. TFPI also undergoes alternative splicing of exon 2 within its 5' untranslated region. The role of exon 2 splicing in translational regulation of human TFPI isoform expression is investigated.
Exon 2 splicing occurs in TFPIα and TFPIβ transcripts. Human tissue mRNA analysis uncovered a wide variability of exon 2 expression. Polysome analysis revealed a repressive effect of exon 2 on TFPIβ translation but not on TFPIα. Luciferase reporter assays further exposed strong translational repression of TFPIβ (90%) but not TFPIα. Use of a Morpholino to remove exon 2 from TFPI mRNA increased cell surface expression of endogenous TFPIβ. Exon 2 also repressed luciferase production (80% to 90%) when paired with the β-actin 3' untranslated region, suggesting that it is a general translational negative element whose effects are overcome by the TFPIα 3' untranslated region.
Exon 2 is a molecular switch that prevents translation of TFPIβ. This is the first demonstration of a 5' untranslated region alternative splicing event that alters translation of isoforms produced via independent 3' splicing events within the same gene. Therefore, it represents a previously unrecognized mechanism for translational control of protein expression. Differential expression of exon 2 denotes a mechanism to provide temporal and tissue-specific regulation of TFPIβ-mediated anticoagulant activity.
组织因子途径抑制剂(TFPI)通过抑制 TF 激活的因子 VII、激活的因子 X 和早期凝血酶原酶来阻止凝血的启动。人类产生两种 3' 剪接变体,TFPIα 和 TFPIβ,它们在血管内皮细胞和血小板中差异表达,并具有影响其抑制功能的不同结构特征。TFPI 还在其 5' 非翻译区的内含子 2 中发生选择性剪接。研究内含子 2 剪接在人类 TFPI 同工型表达的翻译调控中的作用。
内含子 2 剪接发生在 TFPIα 和 TFPIβ 转录本中。人类组织 mRNA 分析揭示了内含子 2 表达的广泛变异性。多核糖体分析显示内含子 2 对 TFPIβ 翻译具有抑制作用,但对 TFPIα 没有。荧光素酶报告基因测定进一步暴露了 TFPIβ 的强烈翻译抑制(90%),而不是 TFPIα。使用 Morpholino 从 TFPI mRNA 中去除内含子 2 增加了内源性 TFPIβ 的细胞表面表达。内含子 2 与 β-肌动蛋白 3' 非翻译区配对时也抑制了荧光素酶的产生(80% 至 90%),这表明它是一种普遍的翻译负性元件,其效应被 TFPIα 3' 非翻译区所克服。
内含子 2 是一种分子开关,可防止 TFPIβ 的翻译。这是首次证明 5' 非翻译区的选择性剪接事件改变了通过同一基因内独立的 3' 剪接事件产生的同工型的翻译。因此,它代表了蛋白质表达翻译调控的一种先前未被认识的机制。内含子 2 的差异表达表示了提供 TFPIβ 介导的抗凝活性的时间和组织特异性调节的机制。